Daiichi says it’s ready to change the standard of care for acute myeloid leukemia — but it’s a work in progress
Close to 4 years ago, Daiichi Sankyo swooped in to buy little San Diego-based Ambit Biosciences for up to $410 million — $315 million of that in cash — to lay its hands on a leukemia drug called quizartinib.
Over the weekend, investigators rolled out the late-stage data that the Japanese company plans to take to regulators at the FDA. The results are statistically significant but unspectacular, with 27% of the patients suffering from treatment-resistant acute myeloid leukemia with FLT3-ITD mutations in the drug arm making it to 52 weeks compared to 20% of the chemo patients in the control arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.